The TAKE Solutions management has implemented the following precautionary measures in response to the COVID-19 pandemic, to protect our customers and staff
Team Lead Mapping:
Geo leaders and HR teams have a complete mapping of both full-time as well as contract resources to identify those in regions at risk, and for appropriate will trigger precautionary and contingency backup measures for continuity of services, based on the extent of risk alert.
Risk Management Plan:
Geo leaders and HR teams have identified and initiated, as appropriate, approvals for staff to work from home, including the period for which such policy will be in effect. Multi-disciplinary BCP teams are continuously in touch with stakeholders, and are prepared to provide required support for both employee welfare as well as customer delivery requirements to the extent possible.
Travel Schedule:
Travel plans have been rearranged, and teleconferencing has been identified as the preferred channel of engagement, even for customer interactions, during this period. Separate travel advisories have been issued through respective location heads.
Enabling efficiencies across the extended organization to create a significant impact
Enabling efficiencies across the extended organization to create a significant impact
Enabling efficiencies across the extended organization to create a significant impact
Navitas Life Sciences
About TAKE Solutions
TAKE at a Glance
Founded in 2000 in Chennai, India, TAKE has grown from strength to strength.
Today, 1500 strong, our key offices are in 6 countries spread across 4 continents.
Investor Relations
Recent News & Media
Navitas Life Sciences’ innovative Regulatory Technology, pharmaREADY®, achieves 200 active customers
Navitas Life Sciences, a TAKE Solutions company, announces that it has achieved...
TAKE Solutions forms strategic partnership with H.I.G. Capital to accelerate growth of Navitas Life Sciences
H.I.G. to support Navitas Life Sciences’ and its continued growth as a ...
US-based firm to acquire 75% stake of Navitas Life Sciences for $101 million
An affiliate of H.I.G. Capital, a US-based alternative investment firm,....
